Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients with high unmet medical need conditions, was featured in an institutional research report by Craig-Hallum Capital Group LLC. The report discusses Craig-Hallum’s research coverage of PCSA and details the company’s experienced management team and its ownership rights to five programs that are de-risked by existing data. The piece reads, “By early next year, PCSA expects to begin three clinical trials – PCS499 in Phase IIb to treat necrobiosis lipoidica (‘NL’), PCS6422 in Phase 1b as an adjunct to the chemotherapy 5-FU, and PCS12852 in Phase IIa to treat constipation. We arrive at a $160M valuation using a DCF model with a blended 12% Probability of Success and 20% WACC.”
To view the full report, visit https://ibn.fm/i1aFT
About Processa Pharmaceuticals Inc.
The mission of Processa is to develop products for which existing clinical evidence of efficacy has already been established for unmet or under-served medical conditions for which patients need treatment options that improve survival and/or quality of life. The company used these criteria to develop its pipeline programs in order to achieve high-value milestones effectively and efficiently using the Processa Regulatory Science approach. The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
BioMedWire is part of the InvestorBrandNetwork